Novartis Allegedly Sat On Drug Rights To Avoid $1B Payment

By Julie Manganis · July 5, 2024, 1:39 PM EDT

Drugmaker Novartis has allowed its right to develop a promising cancer treatment to "wither on the vine" to avoid having to pay nearly $1 billion under an interest purchase agreement with...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login